Neutralizing Antibody Global Market Report 2025

The neutralizing antibody market size has grown rapidly in recent years. It will grow from $230.25 billion in 2024 to $257.81 billion in 2025 at a compound annual growth rate (CAGR) of 12%. Historical growth has been driven by a rise in biologic drug approvals, increased funding for antibody research, higher prevalence of chronic viral infections, growing awareness of immunotherapy, and expanding healthcare spending.

The neutralizing antibody market size is expected to see rapid growth in the next few years. It will grow to $401.16 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. This expected growth will be fueled by a rise in emerging infectious diseases, increasing autoimmune disorders, expansion of antibody-based therapy pipelines, growing demand for precision medicine, and increased interest in targeted therapies. Key trends over the forecast period include a shift toward bispecific and multispecific antibodies, the use of artificial intelligence (AI) in antibody discovery, the development of antibody-drug conjugates, increased use of plant-based antibody production, and a rise in personalized immunotherapy approaches.

The increasing prevalence of infectious diseases is anticipated to drive the growth of the neutralizing antibody market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread from one person to another either directly or indirectly. The growing incidence of these diseases is largely attributed to the rise in global travel, which enables the rapid transmission of pathogens across borders. Neutralizing antibodies play a crucial role in treating infectious diseases by specifically targeting and blocking pathogens, thereby preventing the progression of illness. They contribute to improved patient outcomes by offering precise and timely immune protection. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased to 4,850 in 2023, up by 10.7% from 4,380 cases in 2022. This highlights how the rising prevalence of infectious diseases is bolstering the neutralizing antibody market.

Leading companies in the neutralizing antibody market are prioritizing the development of advanced therapies, including targeted treatments, to more effectively combat infectious diseases by directly neutralizing viruses and preventing their entry into human cells. Targeted therapies are designed to act on specific molecular markers or pathways that are essential for the growth and survival of disease-causing cells, such as those involved in cancers or viral infections. For instance, in February 2022, Eli Lilly and Company, a U.S.-based pharmaceutical firm, received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Bebtelovimab, a neutralizing monoclonal antibody therapy aimed at treating COVID-19. Bebtelovimab is intended for use in patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease, including hospitalization or death. This approval supports timely treatment efforts amid the emergence of new viral variants, thereby aiding in the reduction of disease severity and enhancement of patient outcomes.

In July 2022, Brii Biosciences Limited, a biotechnology firm based in China, collaborated with China Resources Pharmaceutical Commercial Group Co., Ltd. through its joint venture, TSB Therapeutics (Beijing) Co. Ltd., to support the commercialization of amubarvimab/romlusevimab in China. This partnership is focused on expanding access to the treatment for patients with mild to moderate COVID-19 who are at risk of developing severe illness, and accelerating its availability across the country. China Resources Pharmaceutical Commercial Group Co., Ltd. is engaged in the distribution of neutralizing antibody products within China.

Major players in the neutralizing antibody market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., GeNext Genomics, Celltrion Healthcare Co. Ltd, BeiGene Ltd, AbCellera Biologics Inc., BMC Pharmacology and Toxicology, Anthos Therapeutics, Immunome Inc., Sorrento Therapeutics Inc., Tonix Pharmaceuticals, Abwiz Bio, and AXIM Biotechnologies.

North America was the largest region in the neutralizing antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neutralizing antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neutralizing antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A neutralizing antibody is a specific type of antibody that attaches directly to a virus or pathogen, effectively blocking its ability to infect host cells. Its main function is to stop infection by neutralizing the pathogen’s harmful effects, thereby halting disease progression.

Neutralizing antibodies primarily come in two forms: monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are lab-engineered molecules tailored to bind to a specific antigen, such as a virus or cancer cell. These antibodies are used to target a range of viruses, including SARS-CoV-2 (COVID-19), HIV, influenza, Ebola, Zika, and hepatitis C, among others. Distribution channels include direct sales to end-users, distributors, online retailers, and other methods. Applications span across therapeutics, diagnostics, and research and development, catering to end-users such as hospitals and clinics, research institutions, diagnostic laboratories, pharmaceutical companies, and others.

The neutralizing antibody market research report is one of a series of new reports that provides neutralizing antibody market statistics, including neutralizing antibody industry global market size, regional shares, competitors with a neutralizing antibody market share, detailed neutralizing antibody market segments, market trends and opportunities, and any further data you may need to thrive in the neutralizing antibody industry. This neutralizing antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neutralizing antibody market consists of sales of antibody kits, reagents, and related diagnostic and therapeutic products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in usd, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.